How we turn opacity into a score.
Every provider is measured against the same published rubric. The score is the score — it cannot be bought, lobbied, or upgraded by advertising with us.
The six pillars
Weightings reflect what actually protects a patient: who is prescribing, where the medication is compounded, and whether the price you're quoted is the price you pay across the full dose ladder.
- Clinical Protocol & Named Medical Director20 pts
A verifiable MD/DO with state licensure, individualized prescribing over standing orders, and a documented clinical-oversight structure.
- Pharmacy Traceability & Certificate of Analysis20 pts
Named 503A/503B pharmacy partners disclosed in writing, with USP <71> sterility, USP <85> endotoxin, and HPLC potency CoA available on request.
- Real-World Cohort Outcomes & Adverse-Event Disclosure20 pts
Published cohort outcomes, transparent adverse-event reporting, and documented discontinuation rates rather than marketing testimonials.
- All-Inclusive Flat Pricing15 pts
A flat monthly rate across the full titration ladder (2.5 → 15 mg for tirzepatide) with no dose-based upcharges and no hidden fees.
- Lab Integration & Longitudinal Follow-Up15 pts
Quest/Labcorp integration and scheduled clinician check-ins at 4, 12, 26, and 52 weeks — not a one-time intake form.
- Regulatory Clarity10 pts
Semaglutide/tirzepatide base only (no FDA-flagged salt forms), an explicitly stated 503A vs 503B pathway, and active FDA-shortage-status tracking.
Rankings are non-payable.
Rankings are editorial and non-payable. No provider can pay for placement, a higher score, or favorable coverage. GLP Review is affiliate-supported; affiliate relationships never influence scores, which are determined solely by the published v3.0 six-pillar rubric.
When we're wrong, we say so.
Material errors are corrected promptly and logged publicly with the date and nature of the change. Email editorial@glpreview.org to request a correction.
Contact: editorial@glpreview.org